Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...
Potential first-in-class
HutchMed’s Tazverik Receives Conditional Approval from China’s NMPA for Lymphoma Treatment
China-based HutchMed (NASDAQ: HCM, HKG: 0013) has announced receiving conditional marketing approval from the National...
Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery
On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS:...
MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food...
Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials
China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...
Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...
Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...
MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis
The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...
Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...
WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced...
HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...
AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...
Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502
Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered...
TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study
China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...
Amgen’s Tavneos Receives NMPA Approval for ANCA-Associated Vasculitis Treatment in China
US biotechnology company Amgen (NASDAQ: AMGN) has announced that it has received market approval in...
Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...
NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China
NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...
MediLink Therapeutics Partners with Amgen for Clinical Trial in Small Cell Lung Cancer
Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced a partnership with US pharmaceutical giant...